Comparative Pharmacology
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus XYLOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus XYLOCAINE.
LIDOSITE TOPICAL SYSTEM KIT vs XYLOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 mL.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Terminal elimination half-life is approximately 1.5 to 2 hours in adults, prolonged to 2-3 hours in patients with hepatic impairment, and may exceed 5 hours in neonates or patients with heart failure.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Hepatic metabolism (primarily by CYP1A2 and CYP3A4) to metabolites, mainly monoethylglycinexylidide (MEGX) and glycinexylidide (GX); less than 10% excreted unchanged in urine. Renal excretion of metabolites: MEGX (70-80%) and GX (10-20%). Biliary/fecal elimination is minimal.
Category C
Category C
Local Anesthetic
Local Anesthetic